Mehta Rajesh R, Edwards Alison M, Rajpathak Swapnil, Sharma Ajay, Snow Kenneth J, Iglay Kristy
Healthagen Outcomes, New York, NY, USA.
Center for Observational and Real-World Evidence, Merck & Co., Inc., Kenilworth, NJ, USA.
J Clin Transl Endocrinol. 2020 Jan 31;19:100215. doi: 10.1016/j.jcte.2020.100215. eCollection 2020 Mar.
To determine if there is a difference in the outcomes of diabetes patients managed with high, intermediate, or low conformance to diabetes guidelines.
Retrospective database analysis.
This was a retrospective database analysis of adults diagnosed with type 2 diabetes and with glycated hemoglobin (HbA1c) ≥7% (53 mmol/mol) who were commercially insured by, or receiving Medicare benefits through, Aetna. Subjects were classified as having high, intermediate, or low conformance to current guidelines. Six, 12, and 18 months later, health care resource utilization, clinical outcomes, and costs were assessed using multivariable regression analysis to determine whether differences existed between patients with high, intermediate, and low conformance. Regression models were adjusted using pre-index variables, and the results were expressed as incidence rate ratios (IRRs) with 95% confidence intervals (CIs).
A total of 21,171 individuals were included in the analysis. In analyses of patients with low versus high conformance, pharmacy costs were significantly lower over 18 months of outcome assessment (P < 0.001), but diabetes-related outpatient costs were significantly higher (P < 0.001). In analyses of patients with intermediate versus high conformance, diabetes-related outpatient costs were significantly greater at 12 and 18 months (P < 0.001 for both).
Reduced conformance to guidelines leads to higher diabetes-related costs.
确定在糖尿病患者管理中,遵循糖尿病指南程度高、中、低的患者在治疗结果上是否存在差异。
回顾性数据库分析。
这是一项对被诊断为2型糖尿病且糖化血红蛋白(HbA1c)≥7%(53 mmol/mol)的成年人进行的回顾性数据库分析,这些患者由安泰保险公司商业承保或通过该公司领取医疗保险福利。受试者被分类为对当前指南遵循程度高、中或低。在6、12和18个月后,使用多变量回归分析评估医疗资源利用、临床结果和成本,以确定遵循程度高、中、低的患者之间是否存在差异。使用指数前变量对回归模型进行调整,结果以发病率比(IRR)和95%置信区间(CI)表示。
共有21171人纳入分析。在低遵循程度与高遵循程度患者的分析中,在18个月的结果评估期间,药房成本显著更低(P < 0.001),但糖尿病相关门诊成本显著更高(P < 0.001)。在中等遵循程度与高遵循程度患者的分析中,在12个月和18个月时,糖尿病相关门诊成本显著更高(两者均P < 0.001)。
对指南的遵循程度降低会导致更高的糖尿病相关成本。